Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-Ambulant Patients with Duchenne Muscular Dystrophy: An Observational Multicenter Trial-Reference-Cited by-同舟云学术

Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-Ambulant Patients with Duchenne Muscular Dystrophy: An Observational Multicenter Trial

Published:2015-02-02 Issue:2 Volume:10 Page:e0113999
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Seferian Andreea Mihaela,Moraux Amélie,Annoussamy Mélanie,Canal Aurélie,Decostre Valérie,Diebate Oumar,Le Moing Anne-Gaëlle,Gidaro Teresa,Deconinck Nicolas,Van Parys Frauke,Vereecke Wendy,Wittevrongel Sylvia,Mayer Michèle,Maincent Kim,Desguerre Isabelle,Thémar-Noël Christine,Cuisset Jean-Marie,Tiffreau Vincent,Denis Severine,Jousten Virginie,Quijano-Roy Susana,Voit Thomas,Hogrel Jean-Yves,Servais Laurent

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care;K Bushby;Lancet Neurol,2010

2. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management;K Bushby;Lancet Neurol,2010

3. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study;S Cirak;Lancet,2011

4. Systemic administration of PRO051 in Duchenne’s muscular dystrophy;NM Goemans;N Engl J Med,2011

5. Mendell J, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, et al. (2013) Eteplirsen for the treatment of duchenne muscular dystrophy. Ann Neurol.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship Between Hand Strength and Function in Duchenne Muscular Dystrophy and Spinal Muscular Atrophy: Implications for Clinical Trials;Journal of Neuromuscular Diseases;2024-07-02

2. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice;PLOS ONE;2024-01-25

3. Assessment of the upper limb function, strength, and mobility in treatment‐naive children with spinal muscular atrophy Types 2 and 3;Muscle & Nerve;2024-01-18

4. Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era;Frontiers in Neurology;2023-11-13

5. Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy;Journal of Neuromuscular Diseases;2023-07-04